Breaking News

Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax

Dalton to provide formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early phase clinical trials.

By: Contract Pharma

Contract Pharma Staff

Dalton Pharma Services has partnered with the University of Saskatchewan’s Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO-InterVac) in their effort to develop a vaccine for COVID-19. Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada. On April 23rd, the Canadian Federal government committed $1.1 billion to s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters